Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 18 | 2017 | 415 | 2.330 |
Why?
|
| Endometrial Neoplasms | 9 | 2019 | 79 | 2.140 |
Why?
|
| DNA Mismatch Repair | 4 | 2016 | 28 | 1.370 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 291 | 0.700 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 449 | 0.690 |
Why?
|
| Ovarian Cysts | 1 | 2017 | 3 | 0.540 |
Why?
|
| Hysterectomy | 2 | 2017 | 38 | 0.520 |
Why?
|
| Ovary | 2 | 2017 | 113 | 0.510 |
Why?
|
| Vulvar Neoplasms | 2 | 2006 | 10 | 0.480 |
Why?
|
| Middle Aged | 26 | 2019 | 12222 | 0.480 |
Why?
|
| Carcinosarcoma | 2 | 2013 | 4 | 0.480 |
Why?
|
| Postmenopause | 3 | 2014 | 141 | 0.480 |
Why?
|
| Precancerous Conditions | 1 | 2016 | 83 | 0.450 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2014 | 21 | 0.450 |
Why?
|
| CA-125 Antigen | 1 | 2014 | 11 | 0.430 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 14 | 0.430 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2014 | 20 | 0.430 |
Why?
|
| Aged | 21 | 2019 | 8214 | 0.430 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2014 | 19 | 0.430 |
Why?
|
| Retrospective Studies | 7 | 2017 | 2544 | 0.390 |
Why?
|
| Female | 28 | 2019 | 24698 | 0.360 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2017 | 7 | 0.340 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 590 | 0.330 |
Why?
|
| Neoplasm Staging | 5 | 2019 | 374 | 0.290 |
Why?
|
| Aged, 80 and over | 8 | 2019 | 2853 | 0.280 |
Why?
|
| Lymphatic Metastasis | 4 | 2017 | 81 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2011 | 734 | 0.270 |
Why?
|
| Humans | 28 | 2019 | 43102 | 0.270 |
Why?
|
| Neoplasms, Glandular and Epithelial | 4 | 2008 | 57 | 0.260 |
Why?
|
| Adult | 19 | 2019 | 13872 | 0.250 |
Why?
|
| Aneuploidy | 1 | 2004 | 24 | 0.220 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2011 | 863 | 0.220 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 92 | 0.220 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 1723 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 186 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 154 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 290 | 0.170 |
Why?
|
| Carboplatin | 2 | 2019 | 20 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 24 | 0.150 |
Why?
|
| Pelvis | 1 | 2019 | 15 | 0.150 |
Why?
|
| Vagina | 1 | 2019 | 89 | 0.150 |
Why?
|
| Paclitaxel | 1 | 2019 | 64 | 0.140 |
Why?
|
| Case-Control Studies | 11 | 2011 | 1285 | 0.140 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 2008 | 12 | 0.130 |
Why?
|
| Intraoperative Period | 1 | 2017 | 3 | 0.130 |
Why?
|
| False Negative Reactions | 1 | 2017 | 10 | 0.130 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 59 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2017 | 74 | 0.130 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2016 | 8 | 0.120 |
Why?
|
| Hawaii | 6 | 2016 | 2011 | 0.120 |
Why?
|
| Pregnancy, Ectopic | 1 | 2016 | 15 | 0.120 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2016 | 14 | 0.120 |
Why?
|
| Ibuprofen | 1 | 2016 | 34 | 0.120 |
Why?
|
| Lymph Node Excision | 2 | 2006 | 25 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 440 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 245 | 0.120 |
Why?
|
| Menopause | 1 | 2016 | 64 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2019 | 1600 | 0.110 |
Why?
|
| Biopsy | 1 | 2016 | 177 | 0.110 |
Why?
|
| Endometrium | 1 | 2016 | 59 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 146 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2014 | 863 | 0.110 |
Why?
|
| Risk Factors | 6 | 2016 | 3994 | 0.110 |
Why?
|
| Hypoglycemia | 1 | 2013 | 24 | 0.100 |
Why?
|
| Mortality | 1 | 2014 | 175 | 0.100 |
Why?
|
| DNA Repair Enzymes | 1 | 2012 | 22 | 0.090 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2012 | 32 | 0.090 |
Why?
|
| Adenosine Triphosphatases | 1 | 2012 | 83 | 0.090 |
Why?
|
| Pregnancy | 2 | 2016 | 1772 | 0.090 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2011 | 9 | 0.090 |
Why?
|
| Adolescent | 4 | 2017 | 6081 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 213 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 333 | 0.080 |
Why?
|
| Young Adult | 2 | 2019 | 5080 | 0.080 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 201 | 0.080 |
Why?
|
| Interleukin-18 | 1 | 2008 | 17 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 561 | 0.070 |
Why?
|
| Aryldialkylphosphatase | 1 | 2008 | 14 | 0.070 |
Why?
|
| Estrogen Receptor beta | 1 | 2008 | 39 | 0.070 |
Why?
|
| Proteins | 1 | 2011 | 382 | 0.070 |
Why?
|
| Genotype | 5 | 2008 | 800 | 0.070 |
Why?
|
| Carcinoma | 1 | 2008 | 108 | 0.070 |
Why?
|
| Progestins | 1 | 2007 | 11 | 0.070 |
Why?
|
| Alleles | 4 | 2011 | 352 | 0.060 |
Why?
|
| Receptors, Calcitriol | 1 | 2007 | 69 | 0.060 |
Why?
|
| Estrogens | 1 | 2007 | 203 | 0.060 |
Why?
|
| Anovulation | 1 | 2005 | 4 | 0.060 |
Why?
|
| Logistic Models | 4 | 2008 | 1009 | 0.060 |
Why?
|
| Interleukins | 1 | 2004 | 40 | 0.050 |
Why?
|
| Premenopause | 1 | 2005 | 110 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2006 | 1604 | 0.050 |
Why?
|
| Survival Rate | 1 | 2004 | 355 | 0.050 |
Why?
|
| Reproduction | 1 | 2003 | 94 | 0.050 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2002 | 2 | 0.050 |
Why?
|
| Galactose | 1 | 2002 | 9 | 0.050 |
Why?
|
| Lactose | 1 | 2002 | 16 | 0.050 |
Why?
|
| Obesity | 1 | 2011 | 1151 | 0.050 |
Why?
|
| Dairy Products | 1 | 2002 | 34 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 220 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2002 | 220 | 0.040 |
Why?
|
| Contraceptives, Oral | 3 | 2005 | 17 | 0.040 |
Why?
|
| Calcium | 1 | 2002 | 491 | 0.040 |
Why?
|
| Los Angeles | 3 | 2008 | 394 | 0.040 |
Why?
|
| Brachytherapy | 1 | 2019 | 11 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2002 | 469 | 0.040 |
Why?
|
| Risk | 2 | 2008 | 287 | 0.030 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2013 | 25 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 81 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2002 | 587 | 0.020 |
Why?
|
| North Carolina | 1 | 2008 | 127 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 236 | 0.020 |
Why?
|
| Maternal Age | 1 | 2008 | 33 | 0.020 |
Why?
|
| Epithelium | 1 | 2008 | 78 | 0.020 |
Why?
|
| SEER Program | 1 | 2008 | 164 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2008 | 452 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 925 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 455 | 0.020 |
Why?
|
| DNA Damage | 1 | 2008 | 356 | 0.010 |
Why?
|
| Registries | 1 | 2008 | 437 | 0.010 |
Why?
|
| Reproductive History | 1 | 2005 | 27 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 1154 | 0.010 |
Why?
|
| Gravidity | 1 | 2003 | 3 | 0.010 |
Why?
|
| Menstruation | 1 | 2003 | 11 | 0.010 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2003 | 6 | 0.010 |
Why?
|
| Age of Onset | 1 | 2003 | 114 | 0.010 |
Why?
|
| Breast Feeding | 1 | 2005 | 126 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 1857 | 0.010 |
Why?
|
| Second-Look Surgery | 1 | 2002 | 1 | 0.010 |
Why?
|
| Floxuridine | 1 | 2002 | 3 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 2002 | 3 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2002 | 17 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2002 | 14 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2002 | 17 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2002 | 57 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2008 | 1003 | 0.010 |
Why?
|
| Cisplatin | 1 | 2002 | 98 | 0.010 |
Why?
|
| Educational Status | 1 | 2003 | 339 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2004 | 760 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 375 | 0.010 |
Why?
|
| California | 1 | 2002 | 548 | 0.010 |
Why?
|
| Prognosis | 1 | 2002 | 861 | 0.010 |
Why?
|